UK Markets open in 7 hrs 30 mins

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.8038+0.0060 (+0.75%)
At close: 04:00PM EDT
0.7992 -0.00 (-0.57%)
After hours: 04:46PM EDT

Brooklyn ImmunoTherapeutics, Inc.

Building A
Suite 2100 140 58th Street
Brooklyn, NY 11220
United States
212 582 1199

Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Lynn Sadowski Mason M.S.Exec. VP of Clinical Operations362.5kN/A1979
Mr. Ronald Guido M.S.Chief Devel. Officer & Sec.382.5kN/A1957
Dr. Howard J. Federoff M.D., Ph.D.CEO, Pres & DirectorN/AN/A1953
Ms. Sandra M. GurrolaVP of Fin.N/AN/A1967
Dr. Monil Shah M.B.A., Pharm.D.Chief Operating OfficerN/AN/AN/A
Dr. Kevin A. D'Amour Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Jay SialChief Admin. OfficerN/AN/AN/A
Dr. Roger Sidhu M.D.Chief Medical OfficerN/AN/AN/A
Ms. Susan McClatcheyVP & Head of QualityN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Corporate governance

Brooklyn ImmunoTherapeutics, Inc.’s ISS governance QualityScore as of 1 February 2022 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.